Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes

NCT ID: NCT05830422

Last Updated: 2024-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-01

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this observational study is to provide basic data for predicting and analyzing the occurrence and causes of delayed cognitive impairment, an important factor in the quality of life, among discharged patients who have received targeted temperature management therapy and experienced favorable neurological outcomes after out-of-hospital cardiac arrest.

The main questions it aims to answer are:

* Can we identify abnormal areas in the brains of patients with delayed cognitive impairment using Brain MRI or positron emission tomography (PET) imaging?
* Is it possible to predict delayed cognitive impairment using biomarkers?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. For study subjects who survived after out-of-hospital cardiac arrest, prognosis was evaluated using Cerebral Performance Category (CPC) scores on days 10-14 after return of spontaneous circulation (ROSC). A CPC score of 1-2 indicates a good neurological prognosis, while a score of 3-5 indicates a poor neurological prognosis. Only subjects with CPC scores of 1-2 were included in this study.
2. Blood samples were collected through venous puncture at days 10-14, 3 months, and 6 months after ROSC, and the obtained blood was drawn into an serum separating tube (SST) bottle without anticoagulants, then centrifuged within 60 minutes after collection (at 3,000rpm for at least 10 minutes) and divided into tubes. The processed tubes were stored at -70°C.

* The storage period of the samples is 5 years from the date of collection, and they are stored in a coded manner for anonymization.
* The Human Neurology 4-ples A 2.0 Assay Kit (including neurofilament light chain, Tau protein, ubiquitin carboxyl terminal esterase L1 protein \[UCHL1\], and glial fibrillary acidic protein antibody) was analyzed using the single molecule protein detection (SIMOA) analysis machine, and neuron-specific enolase (NSE) in the blood was analyzed together as a reference point to assess the usefulness of each biomarker.
3. Through the Seoul Neuropsychological Screening Battery (SNSB), attention, language and related functions, visuospatial function, memory, frontal lobe and executive function, and other related functions can be assessed. The test is conducted by a specialist clinical psychologist for 1 hour and 30 minutes to 2 hours, and the results are analyzed by Professor Oh Eung-Seok, a neurologist. The presence of cognitive impairment is assessed by conducting tests at 10-14 days, 3 months, and 6 months after ROSC for out-of-hospital cardiac arrest patients with CPC 1-2 points who have passed 10-14 days since ROSC. In addition, through detailed item analysis of the SNSB, functional abnormalities and affected areas (such as the frontal lobe, parietal lobe, temporal lobe, and occipital lobe) are analyzed.
4. We consulted with the departments of radiology, nuclear medicine, and neurology professors to establish the optimal fluorine-18 (18F) fluorodeoxyglucose (FDG) PET \& MRI examination protocol. The first MRI examination was performed 72-96 hours after ROSC, as recommended by international treatment guidelines for predicting neurological prognosis. The first \[18F\]-FDG PET examination was performed at 10-14 days after ROSC, as it may result in false positives if performed too early in cardiac arrest patients. A minimum of 10 days is recommended before performing the examination. If cognitive impairment is observed in the SNSB examination at 3 months after ROSC, a second \[18F\]-FDG PET \& MRI examination is performed. If the cognitive function is normal at 6 months, the examination is performed regardless of cognitive impairment.
5. Prediction and analysis of delayed cognitive impairment and cause analysis in out-of-hospital cardiac arrest patients with good neurological outcomes
6. Delayed cognitive impairment is defined based on the SNSB results, and is defined as the positive group. For biomarkers, differences between the positive and negative groups are determined at each time point, and the predictive power and cut-off values are determined using area under the receiver operating characteristics curve. For images, the functional or anatomical differences between the two groups are compared.
7. Predictive power analysis Through SNSB, the patient's cognitive impairment and the time point of recognition are measured, and the level of biomarkers tested prior to the recognition of impairment is checked to analyze the predictive power. Therefore, the time points for predictive power analysis are 10-14 days, 3 months, and 6 months after ROSC. The first and second \[18F\]-FDG PET \& MRI findings are analyzed to identify differences between the cognitive impairment group and the normal group. Using multiple modes combining clinical data, biomarkers, \[18F\]-FDG PET, MRI, etc., a predictive model for delayed cognitive impairment is developed.
8. Cause analysis Investigate the impairment findings and location using the continuously measured SNSB test values. Analyze the first and second \[18F\]-FDG PET and MRI findings to investigate the functional or anatomical abnormalities occurring in patients with cognitive impairment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrest, Out-Of-Hospital Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Good neurological outcome

Patients who showed good neurological outcomes with CPC scores of 1-2 at discharge

nothing

Intervention Type OTHER

Follow-up observation was conducted without any intervention in an outpatient setting.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nothing

Follow-up observation was conducted without any intervention in an outpatient setting.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who visited the hospital emergency room due to cardiac arrest within 60 months after Institutional Review Board (IRB) approval
* Patients with Glasgow Coma Scale (GCS) less than 8 points after spontaneous circulation recovery
* Patients who are 18 years old or older
* Patients who underwent targeted temperature management (TTM)
* Patients who showed good neurological outcomes with CPC 1-2 points after evaluating the prognosis on days 10-14 after ROSC

Exclusion Criteria

* Under 18 years of age
* cardiac arrest cause is trauma
* Patients who have not undergone targeted temperature management
* Patients treated with extracorporeal membrane oxygenation (ECMO)
* Patients who were not able to undergo SNSB testing
* Patients who could not be followed up until 6 months after ROSC
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chungnam National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jung Soo Park, MD.Phd

Role: STUDY_CHAIR

(35015) Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

박정수

Daejeon, Seo-gu, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Cronberg T, Greer DM, Lilja G, Moulaert V, Swindell P, Rossetti AO. Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation. Lancet Neurol. 2020 Jul;19(7):611-622. doi: 10.1016/S1474-4422(20)30117-4.

Reference Type RESULT
PMID: 32562686 (View on PubMed)

Bronnick K, Evald L, Duez CHV, Grejs AM, Jeppesen AN, Kirkegaard H, Nielsen JF, Soreide E. Biomarker prognostication of cognitive impairment may be feasible even in out-of hospital cardical arrest survivors with good neurological outcome. Resuscitation. 2021 May;162:396-402. doi: 10.1016/j.resuscitation.2021.02.025. Epub 2021 Feb 22.

Reference Type RESULT
PMID: 33631291 (View on PubMed)

Moulaert VR, Verbunt JA, van Heugten CM, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest: a systematic review. Resuscitation. 2009 Mar;80(3):297-305. doi: 10.1016/j.resuscitation.2008.10.034. Epub 2008 Dec 30.

Reference Type RESULT
PMID: 19117659 (View on PubMed)

Elliott VJ, Rodgers DL, Brett SJ. Systematic review of quality of life and other patient-centred outcomes after cardiac arrest survival. Resuscitation. 2011 Mar;82(3):247-56. doi: 10.1016/j.resuscitation.2010.10.030. Epub 2011 Jan 8.

Reference Type RESULT
PMID: 21216080 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CNUH 2022-10-059-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.